FFO
PVLA icon

Fortitude Family Office’s Palvella Therapeutics PVLA Stock Holding History

Fortitude Family Office’s Portfolio PVLA Stock Details PVLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$690 Hold
5
– – ﹤0.01% 2333
2026
Q2 		$764 Sell
5
-5
-50% -$607 ﹤0.01% 1849
2026
Q1 		$1.25K Buy
10
+4
+67% +$417 ﹤0.01% 1448
2025
Q4 		$628 Buy
+6
New +$512 ﹤0.01% 1623

Other funds holding PVLA

CAM
Clio Asset Management Charlottesville, Virginia $119M AUM 1.1% 1-Year Est. Return
Avior Wealth Management
Avior Wealth Management Omaha, Nebraska $3.79B AUM 15.36% 1-Year Est. Return
GAMMA Investing
GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return
Eastern Bank
Eastern Bank Boston, Massachusetts $6.58B AUM 23.57% 1-Year Est. Return
Farther Finance Advisors
Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return
CoreCap Advisors
CoreCap Advisors Southfield, Michigan $3.48B AUM 21.43% 1-Year Est. Return
EP
Essential Partners Rancho Santa Fe, California $219M AUM 37.92% 1-Year Est. Return
NFSG
Newbridge Financial Services Group Boca Raton, Florida $868M AUM 42.47% 1-Year Est. Return

Fortitude Family Office's PVLA Position: Q3 2026 in Review

Fortitude Family Office held its Palvella Therapeutics (PVLA) position steady in Q3 2026 at 5 shares worth $690. The position accounts for ﹤0.01% of the portfolio, ranked #2333.

Fortitude Family Office first reported a position in PVLA in Q4 2025 and has held it in 4 quarters since. The position peaked at $1.25K in Q1 2026. 9 funds tracked by Wall St. Rank hold PVLA as of Q3 2026.

  • Fortitude Family Office held 5 shares of Palvella Therapeutics worth $690 as of Q3 2026.
  • Fortitude Family Office left its Palvella Therapeutics share count unchanged in Q3 2026.
  • Palvella Therapeutics made up ﹤0.01% of Fortitude Family Office's portfolio in Q3 2026, its #2333 holding.
  • Fortitude Family Office first reported a position in Palvella Therapeutics in Q4 2025 and has held it in 4 quarters since.
  • Fortitude Family Office's Palvella Therapeutics position peaked at $1.25K in Q1 2026.
  • 9 funds tracked by Wall St. Rank held Palvella Therapeutics as of Q3 2026.

Based on Fortitude Family Office's 13F filing for Q3 2026, filed 14 Oct 2026.